Delivery Order SPE2DB20D1100-SPE2DB25FE0QA
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order contract valued at approximately $42,601.58 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, scheduled for completion on June 20, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,325.03 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on July 14, 2025, with an ultimate completion date of July 15, 2025. This firm fixed-price delivery order, which carries no set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of pharmaceutical supply services under...
- The Defense Logistics Agency awarded a delivery order valued at $12,806.82 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 26, 2025. This firm fixed price, non-competitive delivery order will be fulfilled from the vendor's place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of August 27, 2025. The award represents a single transaction under AmerisourceBergen's broader federal pharmaceutical supply portfolio serving...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,928.20 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on May 27, 2025, with an ultimate completion date of May 28, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was awarded through open competition. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $96,699.54 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on September 5, 2025, with completion scheduled for September 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors with a ceiling value of $34,200.83 under a firm fixed price contract type. The order was competitively awarded without set-aside designations and is scheduled for completion by August 1, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same municipality. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors with a contract ceiling value of $9,937.75 under firm fixed pricing. The award, issued on August 28, 2025, with an ultimate completion date of August 29, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX). The place of performance is...
- The Defense Logistics Agency (DLA) awarded a $38,968.29 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors. This is a firm fixed price, non-set-aside delivery order with performance through September 5, 2025, and fulfillment from the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $38,528.12 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on June 18, 2025, with an ultimate completion date of June 20, 2025. This non-competitive, firm fixed-price delivery order will be fulfilled at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's broader Indefinite Delivery Contract with...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE0QADelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,118.96 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors. This firm fixed-price delivery order, issued on September 19, 2025, with an ultimate completion date of September 22, 2025, represents a routine pharmaceutical procurement under a non-set-aside competitive process. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's headquarters. This delivery order operates as a child contract under AmerisourceBergen's substantial $1 billion indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX and extending through December 2026. AmerisourceBergen serves as a critical pharmaceutical prime vendor for the Defense Health Agency and broader military healthcare systems, supplying a comprehensive range of medications, vaccines, and medical supplies through the global pharmaceutical support vehicle. The company's extensive federal contract portfolio demonstrates proven capability in meeting DoD medical supply requirements across multiple therapeutic domains, supporting both active-duty personnel and military healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 9/19/25 |